Turtle, the slide that you are referencing in post 132688 appears to be indicating that the mOS is only 15-17 months with SOC ... this would be without DCVax-L .... so this might be the expected mOS for the placebo group who never receive the real DCVax-L.
So this is the OS that DCVax-L will hopefully beat by a wide margin.
I believe that some folks are speculating that the mOS for the Treatment group might wind up at 22+ months (or even around 30 months). I am not clear on where alphapuppy thinks the mOS for treatment group might come in at? Of course 22 to 30 months OS would be a great improvement over merely 15 to 17 months ... so this would bode well.
Of course the above all relates to the Secondary Endpoint.
It would be interesting to get an idea from folks on where they believe the PFS will come in at ... for the trial as a whole, and best guess for the placebo patients (SOC) versus the treated patients.
And ... it would be nice to have an estimate of OS for the patients who received DCVax-L from the beginning of their trial enrollment, versus the OS for those placebo patients who progressed and then crossed over.
Market Data 
Markets 
AI
